共 50 条
- [2] Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positivemetastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial (vol 7, e214761, 2021)JAMA ONCOLOGY, 2022, 8 (09) : 1359 - 1359Zhou, C.Ramalingam, S. S.Kim, T. M.
- [3] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical TrialJAMA ONCOLOGY, 2021, 7 (12) : 1772 - 1781Zhou, CaicunRamalingam, Suresh S.Kim, Tae MinKim, Sang-WeYang, James Chih-HsinRiely, Gregory J.Mekhail, TarekNguyen, DannyCampelo, Maria R. GarciaFelip, EnriquetaVincent, SylvieJin, ShuGriffin, CelinaBunn, VeronicaLin, JianchangLin, Huamao M.Mehta, MinalJanne, Pasi A.
- [4] PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S487 - S488Garcia Campelo, M. R.Zhou, C.Ramalingam, S. S.Lin, H. M.Kim, T. M.Riely, G. J.Mekhail, T.Nguyen, D.Biber, J.Romero, H.Goodman, E.Popat, S.Janne, P. A.
- [5] A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancerCANCER, 2024, 130 (05) : 683 - 691van Veggel, Bianca A. M. H.van der Wekken, Anthonie J.Paats, Marthe S.Hendriks, Lizza E. L.Hashemi, Sayed M. S.Daletzakis, Antoniosvan den Broek, DaanBosch, Linda J. W.Monkhorst, KimSmit, Egbert F.de Langen, Adrianus J.
- [6] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy AnalysisINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)Illini, OliverSaalfeld, Felix CarlChristopoulos, PetrosDuruisseaux, MichaelVikstroem, AndersPeled, NirDemedts, IngelDudnik, ElizabethEisert, AnnaHashemi, Sayed M. S.Janzic, UrskaKian, WaleedMohorcic, KatjaMohammed, SaaraSilvoniemi, MariaRothschild, Sacha I.Schulz, ChristianWesseler, ClaasAddeo, AlfredoArmster, KarinItchins, MalindaIvanovic, MarijaKauffmann-Guerrero, DiegoKoivunen, JussiKuon, JonasPavlakis, NickPiet, BerberSebastian, MartinVelthaus-Rusik, Janna-LisaWannesson, LucianoWiesweg, MarcelWurm, RobertAlbers-Leischner, CorinnaAust, Daniela E.Janning, MelanieFabikan, HannahHerold, SylviaKlimova, AnnaLoges, SonjaSharapova, YanaSchuetz, MaretWeinlinger, ChristophValipour, ArschangOverbeck, Tobias RaphaelGriesinger, FrankJakopovic, MarkoHochmair, Maximilian J.Wermke, Martin
- [7] Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy AnalysisWIENER KLINISCHE WOCHENSCHRIFT, 2024, 136 : S534 - S535Illini, O.Saalfeld, F. C.Christopoulos, P.Duruisseaux, M.Vikstrom, A.Peled, N.Demedts, I.Dudnik, E.Eisert, A.Hashemi, S. MsJanzic, U.Kian, W.Mohorcic, K.Mohammed, S.Silvoniemi, M.Rothschild, S. I.Schulz, C.Wesseler, C.Addeo, A.Armster, K.Itchins, M.Ivanovic, M.Kauffmann-Guerrero, D.Koivunen, J.Kuon, J.Pavlakis, N.Piet, B.Sebastian, M.Velthaus-Rusik, J. -L.Wannesson, L.Wiesweg, M.Wurm, R.Albers-Leischner, C.Aust, D. E.Janning, M.Fabikan, H.Herold, S.Klimova, A.Loges, S.Sharapova, Y.Schuetz, M.Weinlinger, C.Lang-Stoeberl, A.Valipour, A.Overbeck, T. R.Griesinger, F.Jakopovic, M.Hochmair, M. J.Wermke, M.
- [8] Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerEXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 95 - 106Yang, James Chih-HsinZhou, CaicunJanne, Pasi A.Ramalingam, Suresh S.Kim, Tae MinRiely, Gregory J.Spira, Alexander, IPiotrowska, ZofiaMekhail, TarekCampelo, Maria Rosario GarciaFelip, EnriquetaBazhenova, LyudmilaJin, ShuKaur, ManmitDiderichsen, Paul M.Gupta, NeerajBunn, VeronicaLin, JianchangChurchill, EricMehta, MinalNguyen, Danny
- [9] Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm open-label, multicentre, phase 2 trialLANCET RESPIRATORY MEDICINE, 2024, 12 (03): : 217 - 224Wang, MengzhaoFan, YunSun, MeiliWang, YongshengZhao, YanqiuJin, BoHu, YingHan, ZhigangSong, XiaLiu, AnwenTang, KejingDing, CuiminLiang, LiWu, LinGao, JunzhenWang, JianghongCheng, YingZhou, JianyingHe, YongDong, XiaorongYao, YuYu, YanWang, HuijieSun, SiHuang, JiananFang, JianLi, WenWang, LinRen, XiubaoZhou, ChengzhiHu, YanpingZhao, DahaiYang, RunxiangXu, FeiHuang, YijiangPan, YueyinCui, JiuweiXu, YanYang, ZhenfanShi, Yuankai
- [10] Mobocertinib (TAK-788) in epidermal growth factor receptor gene (EGFR) exon 20 insertion mutation-positive (EGFRex20ins+) metastatic non-small cell lung cancer (mNSCLC): results from the platinum-pretreated patients (PPP) cohort of a phase 1/2 studyLUNG CANCER, 2022, 165 : S30 - S31Popat, SanjayRamalingam, SureshKim, Tae MinYang, JamesRiely, GregoryMekhail, TarekNguyen, DannyGarcia Campelo, Maria RosarioFelip, EnriquetaSpira, AlexanderPiotrowska, ZofiaBazhenova, LyudmilaVincent, SylvieJin, ShuGriffin, CelinaDiderichsen, PaulGupta, NeerajBunn, VeronicaLin, JianchangLin, HuamaoChurchill, EricMehta, MinalZhou, CaicunJanne, Pasi